Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rapcabtagene autoleucel versus investigator-choice treatment in severe refractory idiopathic inflammatory myopathies
NL-OMON60010Phase 2Suspended
- Sponsor
- Novartis
- Start
- May 2026
- Modality
- CAR-T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies, Vaccines & Immunotherapeutics, Gene Therapies
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of rapcabtagene autoleucel in Autoimmune Myopathies (2 arms), sponsored by Novartis. Started May 2026; status: suspended.
02
Drugs
rapcabtagene autoleucel
03
Conditions
Autoimmune Myopathies
Beyond the preview
Go deeper on NL-OMON60010.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON60010.